GFG Capital’s Neurocrine Biosciences NBIX Stock Holding History

GFG Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19	Closed	-$2.39K	–	246
2025 Q2	$2.39K	Buy	+19	New	+$2.18K	﹤0.01%	310

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GFG Capital's NBIX Position: Q3 2025 in Review

GFG Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 19 shares — an estimated $2.39K sold.

GFG Capital first reported a position in NBIX in Q2 2025 and held it in 1 quarter. The position peaked at $2.39K in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

GFG Capital reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 19 Neurocrine Biosciences shares in Q3 2025, an estimated $2.39K.
GFG Capital first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 1 quarter.
GFG Capital's Neurocrine Biosciences position peaked at $2.39K in Q2 2025.
649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.